In this week’s health tech round up we take a look at 23andMe’s commitment to Parkinson’s research and partnership with The Michael J. Fox Foundation; Imprivata and Microsoft’s collaboration to address challenges healthcare customers face along the digital transformation journey; Boston Scientific’s FDA approval of its Stent and LetsGetChecked’s $30 million funding round; as well as how With a deal between NHS Digital and Splunk Enterprise, now enables local agencies to access real-time data.

Top Stories

23andMe, Michael J. Fox Foundation partner on platform for Parkinson’s research

23andMe has announced its partnership with The Michael J. Fox Foundation for Parkinson’s research. Launching a new data and analytics platform, the partnership will be dedicated to researching the common neurodegenerative disease. The new platform, Fox DEN will include patient surveys, genetic data and data exploration tools. Users will be able to submit surveys relating to their symptoms and provide information about their daily activities, which will be paired with 23andMe customer genetic insights to help with future studies.

Imprivata and Microsoft collaborate to create end-to-end IAM cloud platform

In collaboration with Microsoft, Healthcare IT security company Imprivata announced it will create an Identity and Access Management (IAM) cloud platform for healthcare. The platform aims to address challenges healthcare customers face along the digital transformation journey. The first phase of the collaboration has been launched as Healthcare Seamless SSO, allowing a single sign-on to all shared clinical workstations, extending the tap-in and tap-out functions of the existing Imprivata OneSign for healthcare customers. Chris Sakalosky, Vice President, Microsoft US health & life sciences said: “This product integration with Imprivata OneSign is the exact type of technological solution that we’re proud to offer to our healthcare customers.”

Boston Scientific wins FDA approval for Vici stent

Boston Scientific has received FDA approval for its Vici Venous Stent, a self-expanding nitinol device. The device is designed to treat iliofemoral venous obstructive disease, working to restore blood flow back to the heart. Aiming to target over 1.1 million patients in the US and Western Europe affected by the disease, the medtech company is expanding its market as its Venovo stent was authorised to trea ilifemoral venous occlusive disease in the US earlier this year. This comes after Medtronic’s study for its Abre stent system launched in January.

LetsGetChecked Announces $30 Million in Series B Financing

The direct-to-consumer at home health testing platform LetsGetChecked has announced the closing of $30 million in its Series B round. As a partner of health devices such as Apple Health, Fitbit and Garmin, LetsGetChecked enables customers to access their health data via a health dashboard, by combining lab results with wearable data in real time. This allows users to receive information and warnings about their health, including cholesterol, thyroid, cardiovascular and more. Currently serving the US, Canada and Europe, the platform is using the funding to continue scaling the company’s consumer brand, and to expand its manufacturing and logistical capabilities through investment in its technology.

NHS Digital data monitoring and analytics available to NHS organisations

NHS Digital is enabling NHS organisations access to a data monitoring and analytics platform which will allow them to make better use of machine generated information. With a deal between NHS Digital and Splunk Enterprise, local agencies will now be able to access real-time data, reduce the risk of service issues and have a more cost-effective approach to obtaining insight from machine data. The Associate Director for Platforms and Infrastructure at NHS Digital said; “Splunk Enterprise has been a key strategic product for NHS Digital for several years and has had a real benefit to ensuring the systems and platforms that the NHS rely on are monitored and available to support patient care.”

You’ve read this far…
Share: